Psychedelic Medicine – What’s Missing From the ‘New Cure’ Narrative?

Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Chemical Collective or any associated parties.

Psychedelics are having a moment. Clinics charge £5,000 for MDMA-assisted therapy. Start-ups race to patent synthetic psilocybin. Politicians debate legalisation. But here’s the problem: none of this is groundbreaking. Humans have used psychedelics to treat trauma for millennia. The real story isn’t innovation – it’s erasure.

Take ayahuasca. Indigenous Amazonian groups have brewed it for centuries to process grief and ancestral suffering. In Mexico, psilocybin mushrooms were central to Mazatec rituals long before Western therapists coined the term “integration”. These practices weren’t obscure – they were targeted. Spanish colonists demonised them as witchcraft. Victorian-era missionaries labelled them primitive. By the 20th century, Western medicine dismissed them as irrelevant.

Now, as psychedelics go mainstream, the same communities that preserved these traditions face exclusion. Corporations trademark indigenous plant knowledge. Retreat centres in Costa Rica commodify sacred ceremonies. Trauma healing gets rebranded as a self-help trend, stripped of its cultural roots.

This isn’t just about giving credit where it’s due. It’s about asking why modern medicine only values these tools once they’re repackaged – and who loses when history repeats itself.

Prehistoric Roots: Psychedelics Weren’t Invented by Hipsters

The notion that psychedelics are a modern phenomenon collapses under the weight of archaeological evidence. Humans have been consuming mind-altering plants for millennia – not for Instagram-worthy epiphanies, but to cope with the brutal realities of prehistory. Take the 6,000-year-old mural in Spain’s Selva Pascuala cave, which clearly depicts Psilocybe hispanica mushrooms. Or the peyote buttons found in Texas, buried alongside ritual tools and dated to 5,000 BCE. These weren’t leftovers from a Stone Age rave. They were deliberate, embedded in survival strategies.

Life for early humans was harsh: predation, injury, infanticide, starvation. Trauma wasn’t a clinical concept – it was a daily reality. Psychedelics likely played a pragmatic role here. Shared hallucinogenic experiences could have forged group cohesion, a necessity when losing even one member threatened collective survival. Imagine a wounded hunter, psychologically shattered after a bear attack, reintegrated into the tribe through a mushroom ceremony. No therapists, no jargon – just communal coping.

But let’s ditch the rose-tinted goggles. Modern retellings often paint prehistoric psychedelic use as a harmonious, spiritually elevated practice. The truth? These substances were tools, not magic. Bad trips happened. Power dynamics skewed rituals. Some groups probably abused them. Yet despite the risks, these cultures iterated on their use across generations, developing what we’d now call “protocols” through trial and error.

Today’s researchers are just starting to decode this buried wisdom. A 2023 study found that psilocybin increases emotional empathy – a trait critical for hunter-gatherer cooperation. Another paper theorises that early human consciousness evolved alongside psychedelic plants, a feedback loop of brain chemistry and ecology. Yet for all their high-tech tools, scientists still can’t replicate the cultural container that made these substances effective. The past holds answers, but we’re still asking the wrong questions.

Sacred Traditions

Indigenous psychedelic practices aren’t spiritualised self-care – they’re sophisticated systems for trauma repair, honed over centuries. Consider the Shipibo-Conibo people of the Peruvian Amazon. Their ayahuasca ceremonies aren’t freelance journeys of “self-discovery”. They’re tightly scripted rituals where icaros (medicine songs) act as sonic scaffolding, guiding participants through destabilising visions. Get it wrong, and the experience risks retraumatisation.

In Mexico, the Mazatec approach psilocybin mushrooms with similar rigour. Healing sessions (veladas) happen at night, led by a curandera who dictates dosage, sets intentions, and interprets visions. There’s no casual “tripping”. The mushrooms, called nti si tho (“the sacred ones”), are treated as non-human teachers – a far cry from the Western framing of psychedelics as brain-altering drugs.

These traditions share three pillars modern clinics often miss:

• Collective responsibility: Healing isn’t an individual pursuit. Entire communities participate, reinforcing that trauma exists in a social context.
• Ancestral accountability: Rituals explicitly address intergenerational wounds, like warfare or displacement – issues Western medicine pathologises as “genetic mental illness”.
• Ecosystem integration: Medicines are harvested through reciprocal relationships with land, not synthesised in labs.

Yet this complexity gets flattened in today’s psychedelic boom. Ayahuasca retreats in Ibiza serve vegan diets and promise “ego death” in three days – a checklist approach that ignores Shipibo’s months-long preparations. Psychedelic startups strip rituals of their cultural DNA, rebranding them as “protocols”. It’s not evolution; it’s extraction.

The irony? Modern research keeps tripping over truths indigenous cultures embedded long ago. A 2022 Imperial College London study found ayahuasca’s DMT – long dismissed as mere hallucinogen – triggers neuroplasticity in brain regions linked to traumatic memory. Another paper admits psilocybin therapy’s success hinges on “set and setting”, a concept shamans mastered centuries back.

But validation isn’t the same as justice. When a pharma company patents a synthetic version of ayahuasca, it’s not progress – it’s the latest chapter in a history of colonial theft.

Shamans as the First Therapists: Why Modern Clinics Are Playing Catch-Up

Shamans didn’t need white coats or RCTs to prove their methods worked. For millennia, they’ve operated as hybrid practitioners – part therapist, part ecologist, part historian – using psychedelics to treat trauma long before the DSM-5 pathologised it. Take the Siberian Evenki people, who used Amanita muscaria mushrooms to navigate grief after loss. The shaman didn’t just guide the trip; they contextualised the pain within the tribe’s shared story, transforming personal suffering into collective meaning.

In the Amazon, Shipibo shamans still use ayahuasca to diagnose trauma’s root causes, whether physical, spiritual, or ancestral. During ceremonies, they map visions onto intricate textile patterns called kené, creating a visual language to decode the psyche. Compare this to modern psychedelic therapy, where patients scribble in journals while facilitators take notes. The shaman’s approach isn’t mystical – it’s methodological.

Yet Western medicine continues to rebrand these ancient frameworks. The “integration” phase of clinical trials? That’s a diluted version of the Shipibo’s dieta, where post-ceremony dietary and behavioural restrictions solidify insights. The emphasis on “set and setting”? A nod to the Mazatec’s strict mushroom rituals, timed to lunar cycles and conducted in darkness to minimise distraction.

But here’s the rub: modern clinics often strip these practices of their cultural backbone. A shaman’s authority isn’t just about guiding trips – it’s earned through decades of apprenticeship, ecological knowledge, and community accountability. Yet in the West, a weekend training course can certify someone to “hold space” for trauma patients. The result? A surge in ethical breaches, from therapists overstepping boundaries to retreat leaders appropriating rituals they barely understand.

Science is starting to concede the gap. A 2023 University College London study found that psilocybin therapy’s efficacy drops when divorced from “ritual scaffolding”. Another paper in The Lancet Psychiatry admitted that Western models fail to address collective trauma – a cornerstone of indigenous practice.

The takeaway isn’t that we need more shamans in lab coats. It’s that healing trauma requires more than molecules. It demands respect for the systems that kept these medicines alive – systems modern science still struggles to comprehend.

Colonial Erasure

Colonialism didn’t just steal land – it rewrote history. When Spanish conquistadors invaded the Americas, they didn’t just burn cities; they torched entire systems of healing. Aztec teonanácatl (psilocybin mushroom) rituals were labelled “satanic”. Quechua coca ceremonies were banned as “savagery”. Missionaries replaced communal ayahuasca practices with confessional booths, swapping plant-mediated catharsis for Catholic guilt.

The British Empire followed suit. In 19th-century India, they outlawed cannabis-based bhang rituals, dismissing them as “native superstition” – despite Victorian doctors prescribing opium tinctures for “hysteria”. In Africa, colonisers framed iboga ceremonies as primitive, even as Freudian psychoanalysis (which pathologised trauma as personal weakness) became gospel in Europe.

The fallout was catastrophic. Indigenous healers were jailed or killed. Sacred plants were eradicated or driven underground. Trauma, once understood as a collective wound requiring communal ritual, got reduced to a private flaw to be medicated. By the 20th century, Western medicine had all but erased psychedelics from the therapeutic toolkit – until, of course, white scientists “discovered” them.

Take mescaline. In 1897, German chemist Arthur Heffter isolated the compound from peyote, a cactus central to Native American rituals for centuries. By the 1950s, mescaline was a darling of Western psychiatry, tested on everyone from artists to housewives. Nobody mentioned the Comanche or Huichol peoples, who’d long used peyote to process war trauma and cultural loss.

This pattern repeats today. Pharma companies patent synthetic versions of ayahuasca’s DMT. Psychedelic retreats in Bali market “ancestral healing” – led by Instagram influencers, not indigenous elders. It’s spiritual gentrification: ancestral knowledge gets repackaged as luxury wellness once the original stewards are erased.

But resistance persists. The Native American Church fought for decades to legalise peyote ceremonies, winning exemptions in US law. In Brazil, descendants of enslaved Africans kept ayahuasca traditions alive through religions like Santo Daime, blending them with Christian hymns as both camouflage and rebellion.

The lesson? Colonialism tried to bury psychedelic wisdom. It didn’t count on that wisdom being rooted – or on the people who refuse to let it die.

The Double-Edged Sword of Psychedelic Revival

Today’s psychedelic boom is billed as progress – a fusion of ancient wisdom and cutting-edge science. But scratch the surface, and contradictions emerge. Take MDMA: once a pariah of the War on Drugs, it’s now in Phase 3 trials for PTSD, with some studies showing 67% of patients no longer qualifying for the diagnosis after treatment. The catch? These trials mimic indigenous practices stripped of context. Guides replace shamans; sterile rooms substitute for firelit ceremonies. It works, but at what cost?

The stats are compelling. A 2023 UK study at Imperial College London found psilocybin therapy reduced depression symptoms in 60% of participants – comparable to ayahuasca’s efficacy in Amazonian communities. But while Western researchers fixate on brain scans and serotonin receptors, indigenous healers shrug. “We’ve always known the plants speak,” says María Sabina’s granddaughter, a Mazatec curandera. “Science is just learning to listen.”

Yet the rush to commercialise risks repeating colonial mistakes. Compass Pathways, a UK-based startup, holds patents on synthetic psilocybin formulations – despite the compound existing in nature for millennia. In 2022, the US Patent Office controversially granted a company exclusive rights to a “new” ayahuasca blend, ignoring the Shipibo’s centuries-old brews. Meanwhile, retreat centres charge £8,000 for “authentic” ceremonies led by white facilitators with six weeks’ training.

Not all players are extractive. The Uvá-Wat Collective in Colombia partners with scientists to study ayahuasca’s impact on conflict-related trauma, ensuring indigenous leaders co-design trials and retain IP rights. In Wales, the MycoMeditations project collaborates with local mycologists to revive Celtic psilocybin traditions erased by Christianisation. These efforts hint at a more equitable model – if they can survive pharma’s gold rush.

The stakes go beyond ethics. Psychedelics’ therapeutic power hinges on the very elements modern medicine sidelines: ritual, community, and ancestral reverence. Strip those away, and you’re left with another pill – one that might heal individuals but fails to address trauma’s roots in broken systems.

The renaissance isn’t doomed, but it’s at a crossroads. Respect indigenous sovereignty, and psychedelics could democratise mental healthcare. Prioritise profit, and we’ll end up with a wellness caste system: designer trips for the rich, criminalisation for the rest. History’s watching.

Rewriting the Future Without Repeating the Past

The psychedelic renaissance isn’t a blank slate – it’s a palimpsest. Scratch away the glossy marketing, and you’ll find layers of indigenous knowledge, colonial violence, and capitalist opportunism. Modern medicine stands at a crossroads: Will it partner with the cultures that safeguarded these medicines, or will it become another chapter in the same old story of extraction?

Consider two futures. In one, psychedelic clinics operate like Amazon warehouses – efficiency-obsessed, patent-hoarding, selling “healing” as a privatised commodity. Trauma becomes a technical glitch to be fixed with a chemical key, ignoring the poverty, racism, and ecological collapse that fuel it.

In the other future, psychedelics catalyse a broader reckoning. Indigenous groups lead research partnerships, not as “consultants” but as owners. Urban clinics incorporate ritual elements – not as exotic decor, but as non-negotiable protocol. Governments fund community-based programs, not just pharma trials.

The path isn’t hypothetical. In Canada, the First Nations Health Authority now licenses psychedelic therapists, requiring training in indigenous trauma frameworks. In Brazil, the Santo Daime church successfully sued to protect ayahuasca as cultural heritage, blocking foreign biopiracy. These are blueprints, not outliers.

But blueprints require courage. It means admitting that a molecule alone can’t heal colonial trauma – especially when that molecule’s history is colonial trauma. It means rejecting the lie that science “advances” by erasing its debts to ancestral knowledge.

Psychedelics didn’t survive missionaries, wars on drugs, or corporate patents by accident. They survived because some communities refused to let their stories die. Now, it’s our turn to decide: Will we be allies in that refusal, or just another threat wearing a lab coat?

The medicines are watching…

David Blackbourn | Community Blogger at Chemical Collective

David is one of our community bloggers here at Chemical Collective. If you’re interested in joining our blogging team and getting paid to write about subjects you’re passionate about, please reach out to David via email at blog@chemical-collective.com